Omar Hasan Ali
Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs.
Loo L, Waller M, Moreno C, Cole A, Stella A, Pop O, Jochum A, Ali O, Denes C, Hamoudi Z, Chung F, Aggarwal A, Low J, Patel K, Siddiquee R, Kang T, Mathivanan S, Mackay J, Jochum W, Flatz L, Hesselson D, Turville S, Neely G. Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs. PLoS Biol 2023; 21:e3001967.
09.02.2023Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs.
09.02.2023PLoS Biol 2023; 21:e3001967
Loo Lipin, Waller Matthew A, Moreno Cesar L, Cole Alexander J, Stella Alberto Ospina, Pop Oltin-Tiberiu, Jochum Ann-Kristin, Ali Omar Hasan, Denes Christopher E, Hamoudi Zina, Chung Felicity, Aggarwal Anupriya, Low Jason K K, Patel Karishma, Siddiquee Rezwan, Kang Taeyoung, Mathivanan Suresh, Mackay Joel P, Jochum Wolfram, Flatz Lukas, Hesselson Daniel, Turville Stuart G, Neely G Gregory
Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.
Sinnberg T, Lichtensteiger C, Ali O, Pop O, Risch L, Brugger S, Velic A, Bomze D, Kohler P, Vernazza P, Albrich W, Kahlert C, Abdou M, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat S, Ruetalo N, Buehler P, Scheier T, Jochum W, Kern L, Henz S, Schneider T, Kuster G, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy K, Spengler W, Brutsche M, Macek B, Twerenbold R, Penninger J, Matter M, Flatz L, Jochum A. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. Am J Respir Crit Care Med 2023; 207:38-49.
01.01.2023Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19.
01.01.2023Am J Respir Crit Care Med 2023; 207:38-49
Sinnberg Tobias, Lichtensteiger Christa, Ali Omar Hasan, Pop Oltin T, Risch Lorenz, Brugger Silvio D, Velic Ana, Bomze David, Kohler Philipp, Vernazza Pietro, Albrich Werner, Kahlert Christian, Abdou Marie-Therese, Wyss Nina, Hofmeister Kathrin, Niessner Heike, Zinner Carl, Gilardi Mara, Tzankov Alexandar, Röcken Martin, Dulovic Alex, Shambat Srikanth Mairpady, Ruetalo Natalia, Buehler Philipp K, Scheier Thomas C, Jochum Wolfram, Kern Lukas, Henz Samuel, Schneider Tino, Kuster Gabriela M, Lampart Maurin, Siegemund Martin, Bingisser Roland, Schindler Michael, Schneiderhan-Marra Nicole, Kalbacher Hubert, McCoy Kathy D, Spengler Werner, Brutsche Martin H, Macek Boris, Twerenbold Raphael, Penninger Josef M, Matter Matthias S, Flatz Lukas, Jochum Ann-Kristin
Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 T Cell Responses
Ring S, Królik M, Hartmann F, Schmidt E, Ali O, Ludewig B, Kochanek S, Flatz L. Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 T Cell Responses. Mol Ther Oncolytics 2020; 19:179-187.
10.10.2020Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 T Cell Responses
10.10.2020Mol Ther Oncolytics 2020; 19:179-187
Ring Sandra, Królik Michał Wojciech, Hartmann Fabienne, Schmidt Erika, Ali Omar Hasan, Ludewig Burkhard, Kochanek Stefan, Flatz Lukas
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019; 5:1043-1047.
01.07.2019Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
01.07.2019JAMA Oncol 2019; 5:1043-1047
Berner Fiamma, Hartmann Fabienne, Cheng Hung-Wei, Hönger Gideon, Recher Mike, Goldman Jonathan, Cozzio Antonio, Früh Martin, Neefjes Jacques, Driessen Christoph, Ludewig Burkhard, Hegazy Ahmed N, Jochum Wolfram, Speiser Daniel E, Zippelius Alfred, Läubli Heinz, Bomze David, Diem Stefan, Ali Omar Hasan, Fässler Mirjam, Ring Sandra, Niederer Rebekka, Ackermann Christoph J, Baumgaertner Petra, Pikor Natalia, Cruz Cristina Gil, van de Veen Willem, Akdis Mübeccel, Nikolaev Sergey, Flatz Lukas
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
01.04.2019Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
01.04.2019J Immunother 2019; 42:89-93
Diem Stefan, Risch Martin, Recher Mike, Risch Lorenz, Dummer Reinhard, Levesque Mitchell P, Mangana Joanna, Hillmann Dorothea, Niederer Rebekka, Berner Fiamma, Ali Omar Hasan, Bomze David, Fässler Mirjam, Flatz Lukas
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
08.11.2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
08.11.2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas